iMATRIX-atezolizumab participants and samples
tumor, Cancer
TUMOR, CANCER
The iMATRIX-atezo clinical trial from which collected patient samples were analyzed for the exploratory study herein is registered with ClinicalTrials.gov at As previously describedFrom 28 centers across ten countries, a total of 90 patients were enrolled in the phase 1–2 iMATRIX-atezo clinical trial. Patients were enrolled regardless of sex (sex was self-reported via electronic data capture by clinical trial site staff). Written informed consent was obtained before study participation from each participant, including consent for the collection and use of patients’ samples. Consent was not provided to share sex data in a disaggregated (patient-level) manner and no analyses by sex were conducted as part of the planned clinical study analyses or the study herein. Patients in the safety-evaluable population (Patient samples and sample data (IHC, FoundationOne (F1) sequencing and whole transcriptome sequencing) were shared as appropriate and in accordance with these consents through a research collaboration agreement between Roche/Genentech and the Princess Margaret Cancer Centre. Overall, 75 tumor tissue samples were collected before treatment and were available for analysis. These samples were primarily archival samples or were collected through resection or biopsy during the patient’s screening period for the trial. These samples are termed as ‘pre-treatment’. Eight samples were removed due to failed library preparation or sequencing quality control. We included 66 unique tumor samples in analyses and results described herein (Supplementary Table 